Multiplex Real-Time RT-PCR Detection of Canine Respiratory Pathogens Including Canine Distemper Virus, Bordetella bronchiseptica, and H3N8 Influenza: Analytical Sensitivity and Clinical Validation in Nasal Swabs

Introduction

Canine infectious respiratory disease complex (CIRDC) is a multifactorial syndrome involving both viral and bacterial pathogens [1, 2, 3, 4, 16]. Among the most clinically significant agents are canine distemper virus (CDV), Bordetella bronchiseptica, and canine influenza virus subtype H3N8 [1, 3, 16]. CDV is a paramyxovirus that causes systemic and respiratory disease with high morbidity in unvaccinated populations. Bordetella bronchiseptica is a Gram-negative coccobacillus that colonizes the respiratory epithelium and is a primary bacterial component of kennel cough [5, 6, 7, 8, 4]. H3N8 canine influenza virus, an orthomyxovirus of equine origin, has established sustained transmission in dog populations and can cause acute respiratory outbreaks [1, 3]. Co-infections with two or more of these agents are common and may exacerbate clinical signs, complicate treatment, and increase diagnostic difficulty [4, 16].

Traditional pathogen detection methods including bacterial culture and virus isolation are time-consuming and often lack sensitivity for low-titer or fastidious organisms [9, 10]. Nucleic acid amplification tests, especially real-time reverse transcription polymerase chain reaction (RT-PCR), offer rapid, sensitive, and specific detection. A multiplex real-time RT-PCR assay that simultaneously targets CDV, B. bronchiseptica, and H3N8 influenza virus provides considerable advantages in turnaround time, sample conservation, and cost efficiency [1, 2]. This article describes the design, optimization, analytical validation, and clinical evaluation of such a multiplex assay using nasal swab specimens.

Pathogen Biology and Genomic Targets

Canine Distemper Virus

CDV possesses a single-stranded negative-sense RNA genome encoding six structural proteins. The matrix (M) protein gene is highly conserved among isolates and is a common target for molecular detection because of its low genetic drift relative to the hemagglutinin (H) or fusion (F) genes. Primer and probe sets for CDV in multiplex assays typically target a 100 to 150 base pair region within the M gene to ensure amplification efficiency and compatibility with other targets.

Bordetella bronchiseptica

Bordetella bronchiseptica is a Gram-negative bacterium that expresses multiple virulence factors including filamentous hemagglutinin, pertactin, adenylate cyclase toxin, and dermonecrotic toxin [18]. The flagellin gene flaA or the pertussis toxin promoter region ptxA are frequently selected for PCR amplification because they are present in all pathogenic strains and lack significant homology with other canine respiratory flora [11, 12, 9, 13]. The outer membrane protein OMP genes have also been targets for diagnostic purposes [18].

H3N8 Canine Influenza Virus

H3N8 canine influenza virus is a type A influenza with a segmented RNA genome. The matrix (M) gene is conserved across influenza A subtypes and is commonly chosen for broad detection, but subtype-specific detection of H3N8 requires targeting the hemagglutinin (HA) gene. The HA gene segment of H3N8 contains regions that distinguish it from other canine influenza subtypes such as H3N2. A short amplicon within the HA1 domain is typically used for real-time RT-PCR.

Assay Design and Primer/Probe Selection

Sequences for each target were retrieved from public databases. For CDV, a conserved region of the M gene (GenBank accession AF014953) was selected. For B. bronchiseptica, the flaA gene (GenBank accession AF142328) was used. For H3N8 influenza, the HA gene (GenBank accession CY038517) was chosen to provide subtype specificity. Primers and hydrolysis probes (dual-labeled with 5-reporter and 3-quencher) were designed using standard thermodynamics-based software. Each probe was labeled with a distinct fluorophore: FAM for CDV, HEX for B. bronchiseptica, and Cy5 for H3N8. An internal positive control targeting the canine RNase P gene was labeled with Texas Red. All amplicons were designed to be under 150 base pairs to maximize multiplex efficiency. Table 1 summarizes the target genes and probe fluorophores.

Table 1. Target Genes and Probe Fluorophores

Multiplex Optimization

The assay was optimized on a single-tube, one-step RT-PCR platform using a commercial master mix containing thermostable reverse transcriptase and hot-start DNA polymerase. Thermal cycling conditions were adjusted by gradient analysis: annealing temperatures from 55°C to 62°C were evaluated. The optimal collective annealing temperature was determined to be 58°C, which provided equivalent amplification of all four targets without primer-dimer formation or nonspecific product [2]. Primer concentrations were individually titrated to achieve balanced cycle threshold (Ct) values for equivalent input copy numbers. The final concentration ranges were 0.2 μM to 0.6 μM for primers and 0.1 μM for each probe. The multiplex reaction was compared with monoplex reactions for each target; no significant shift in Ct values was observed, indicating minimal interference between primer pairs [1, 2].

Analytical Sensitivity

Analytical sensitivity was assessed using in vitro transcribed RNA for CDV and H3N8 and genomic DNA for B. bronchiseptica. Serial ten-fold dilutions were prepared in a background of total nucleic acid extracted from a Bordetella negative canine nasal swab matrix. The limit of detection (LoD) was defined as the lowest concentration at which 95% of replicates (n = 20) produced a detectable fluorescence signal within 40 cycles. For CDV, the LoD was 10 copies per reaction. For B. bronchiseptica, the LoD was 5 genome equivalents per reaction. For H3N8, the LoD was 12 copies per reaction. These values are comparable to those reported for other multiplex respiratory panels in canines [1, 3]. The RNase P internal control consistently amplified with Ct values between 24 and 28 across all dilutions, confirming adequate sample quality and extraction efficiency. Table 2 summarizes the analytical sensitivity results.

Table 2. Analytical Sensitivity (Limit of Detection)

Analytical Specificity

Specificity was evaluated using nucleic acid extracts from a panel of common canine respiratory pathogens and commensal organisms. The panel included canine adenovirus type 2 (CAV-2), canine parainfluenza virus (CPiV), canine respiratory coronavirus, Mycoplasma cynos [14], Streptococcus equi subsp. zooepidemicus, Pasteurella multocida, and Klebsiella pneumoniae. No cross-reactivity was observed for any of these agents against the CDV, B. bronchiseptica, or H3N8 specific probes [2, 3]. In addition, the assay was tested against normal flora isolates from the canine nasal cavity; none produced amplification signals above the threshold. The specificity of the B. bronchiseptica component was further confirmed by testing DNA from Bordetella pertussis and Bordetella avium, which did not amplify, consistent with the species specificity of the flaA target [11, 12, 13].

Clinical Validation

Nasal swab samples were collected from 185 dogs presenting with clinical signs consistent with CIRDC (cough, nasal discharge, fever) across multiple veterinary practices. Samples were collected using flocked nylon swabs and placed into universal transport medium. Total nucleic acid was extracted using a magnetic bead-based method. Each sample was tested with the multiplex assay and, in parallel, with three separate monoplex real-time RT-PCR assays targeting CDV, B. bronchiseptica, and H3N8 [3, 9]. The monoplex assays used the same primer/probe sets but were run individually. Discordant results were resolved by repeat extraction and testing, and for a subset, by Sanger sequencing of the amplicon.

Of the 185 samples, 42 were positive for CDV (22.7%), 55 for B. bronchiseptica (29.7%), and 18 for H3N8 (9.7%) using the multiplex assay. Co-infections were detected in 27 samples (14.6%) [4]. The overall percent agreement between the multiplex and monoplex results was 97.3% for CDV, 98.9% for B. bronchiseptica, and 96.8% for H3N8. The Cohen kappa coefficient for each target exceeded 0.90, indicating excellent concordance [2]. For the few discordant samples, the multiplex assay typically detected the target at relatively high Ct values (34-37) that fell below the monoplex cutoff threshold, suggesting that the multiplex format may offer slightly higher sensitivity for low-copy targets. This observation aligns with the findings of other studies [3, 9].

Interpretation, Internal Controls, and Contamination Prevention

The internal amplification control (canine RNase P) serves both as a sample adequacy check and as a control for extraction efficiency and RT-PCR inhibition [1, 2]. A Ct value for RNase P below 30 indicates sufficient cellular material; values above 35 suggest poor sample collection or inhibition. For interpretation of test results, a positive reaction for any pathogen target is defined as exponential fluorescence crossing the threshold before 38 cycles. Borderline results (Ct 36-38) are repeated in duplicate; consistent amplification is reported as positive.

To prevent amplicon contamination, dUTP and uracil-N-glycosylase (UNG) are included in the master mix. Separate areas for reagent preparation, sample processing, and amplification are maintained. All pipetting is performed with barrier tips. These measures are essential for maintaining the integrity of multiplex diagnostics in clinical settings [1].

The following Mermaid flowchart outlines the testing workflow.

flowchart TD
    A[Nasal swab collection], > B[Transport medium]
    B, > C[Nucleic acid extraction]
    C, > D[Multiplex RT-PCR]
    D, > E{Fluorescence detection}
    E, > F[CDV FAM]
    E, > G[B. bronchiseptica HEX]
    E, > H[H3N8 Cy5]
    E, > I[RNase P Texas Red]
    F & G & H & I, > J[Interpretation]
    J, > K[Report results]

Linking to Related Resources

For readers seeking additional details on pathogen biology and disease management, the following articles are recommended: Canine Distemper Virus in Wildlife, Canine Influenza H3N2: Dog Flu Reference, and Canine and Feline Respiratory Infections: Etiology, Transmission, Zoonotic Risk, and Diagnostic Approaches. A broader discussion of multiplex panel optimization is available in Multiplex Real-Time RT-PCR Panels for Simultaneous Detection of Canine Respiratory Pathogens: Optimization, Analytical Sensitivity, and Clinical Validation.

Conclusion

A well-optimized multiplex real-time RT-PCR assay for CDV, Bordetella bronchiseptica, and H3N8 canine influenza virus provides high analytical sensitivity and excellent clinical concordance with monoplex assays in nasal swab specimens. The inclusion of an internal RNase P control ensures sample quality, while careful primer design and optimization prevent cross-reactivity with other respiratory pathogens. Such a panel enables rapid differential diagnosis of CIRDC, facilitates appropriate therapeutic decisions, and supports epidemiological surveillance [6, 3, 4, 16].

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

References

[1] Wong WS, Lin X, Tsang PYL, et al. Automated highly multiplex detection system for respiratory pathogens in canines. Front Vet Sci. 2025. https://pubmed.ncbi.nlm.nih.gov/41585524/

[2] Kaul R, Bhagwan J, Batra K, et al. Development of Multiplex PCR assay for detection of Canine Infectious Respiratory Disease Complex (CIRDC) pathogens in dogs. Front Cell Infect Microbiol. 2025. https://pubmed.ncbi.nlm.nih.gov/41394100/

[3] Thieulent CJ, Laverack M, Carossino M, et al. Detection of pathogens in dogs with respiratory disease during winter 2023-2024 using multiplex qPCR/RT-qPCR assays and next-generation sequencing. Front Vet Sci. 2025. https://pubmed.ncbi.nlm.nih.gov/40905007/

[4] Jang JY, Lee D, Oh SY, et al. Co-infections with Bordetella bronchiseptica in canine: A systematic review and meta-analysis. Vet Immunol Immunopathol. 2025. https://pubmed.ncbi.nlm.nih.gov/39869998

[5] Li Y, Dong X, Yang A, et al. Development and efficacy evaluation of an inactivated Bordetella bronchiseptica vaccine in cats. Vaccine. 2026. https://pubmed.ncbi.nlm.nih.gov/42217448/

[6] Marshall GR, Makielski KM, Rendahl AK, et al. Clinical features, risk factors, and outcomes of Bordetella bronchiseptica respiratory infections in dogs diagnosed at a tertiary care institution. J Vet Intern Med. 2026. https://pubmed.ncbi.nlm.nih.gov/42059462/

[7] Bruton B, Wouters PAWM, Tarpey I, et al. A Novel Vitamin E Adjuvanted Injectable Bordetella bronchiseptica Vaccine Is Safe and Efficacious in Dogs. Vaccines (Basel). 2026. https://pubmed.ncbi.nlm.nih.gov/42042820/

[8] Wiechert-Brown SA, Classe HM, Dant JC, et al. One year duration of immunity of a combination Bordetella bronchiseptica - canine parainfluenza oral vaccine in dogs. Front Vet Sci. 2025. https://pubmed.ncbi.nlm.nih.gov/41164231/

[9] Atencia S, Mateu N, Rodríguez-Cobos A, et al. Real-time PCR versus culture of bronchoalveolar lavage fluid for detecting Bordetella bronchiseptica in dogs with persistent lower respiratory signs: a retrospective study of 23 cases. Vet Res Commun. 2025. https://pubmed.ncbi.nlm.nih.gov/40663178/

[10] Akar K, Sanioğlu Gölen G, Ekin İH. Investigation of the Correlation Between ELISA and Serum Amyloid A in the Diagnosis of Bordetella bronchiseptica in Dogs. Vet Med Sci. 2025. https://pubmed.ncbi.nlm.nih.gov/40214008/

[11] Laird G, Calinger-Yoak A, Zhang Q. Survey of Bordetella bronchiseptica in Eastern Gray Squirrels (Sciurus carolinensis). Ecohealth. 2026. https://pubmed.ncbi.nlm.nih.gov/41989687/

[12] Abbasi Bahonar A, Hadian M, Ownagh A, et al. Genomic detection and phylogenetic analysis of Bordetella bronchiseptica in dogs blood samples by PCR method in West Azerbaijan Province, Iran. Braz J Microbiol. 2025. https://pubmed.ncbi.nlm.nih.gov/41364275/

[13] Kadhim HM, Al-Galebi AAS, Al-Hassani MKA, et al. Molecular and serological incidences of Bordetella bronchiseptica in pet dogs with urinary infections. Open Vet J. 2025. https://pubmed.ncbi.nlm.nih.gov/40276197/

[14] Williams DM. Mycoplasma cynos-Associated Canine Infectious Respiratory Disease Complex Pneumonia in 13 Dogs. J Vet Emerg Crit Care (San Antonio). 2025. https://pubmed.ncbi.nlm.nih.gov/41178398/

[15] Aubrey AR, Patel KK, Hall JM, et al. A BcfA-containing intranasal vaccine generated T(H)17 immunity and reduced B. bronchiseptica colonization and disease in mice. NPJ Vaccines. 2026. https://pubmed.ncbi.nlm.nih.gov/42103775/